Global blood therapeutics, inc. (GBT)
Income statement / Quarterly
Mar'20Dec'19Sep'19Jun'19Mar'19Dec'18Sep'18Jun'18Mar'18Dec'17Sep'17Jun'17Mar'17Dec'16Sep'16Jun'16Mar'16Dec'15Sep'15Jun'15Mar'15Sep'14Jun'14
Revenues [Abstract]
Product sales, net

14,118

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Costs and operating expenses:
Cost of sales

135

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Research and development

39,773

64,990

39,088

36,010

34,468

36,764

33,026

31,573

29,944

31,294

20,952

18,278

17,283

20,908

15,413

13,427

12,415

11,400

12,106

7,082

6,069

4,069

4,315

Selling, general and administrative

47,662

44,585

29,654

24,794

18,055

15,320

12,450

10,914

12,751

10,620

8,228

6,152

6,438

6,552

5,731

4,379

4,302

4,198

2,669

1,506

1,298

1,109

688

Total costs and operating expenses

87,570

101,322

68,742

60,804

52,523

52,084

45,476

42,487

42,695

41,914

29,180

24,430

23,721

27,460

21,144

17,806

16,717

15,598

14,775

8,600

7,420

5,200

5,128

Related party expenses

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

0

12

53

22

125

Loss from operations

-73,452

-99,214

-68,742

-60,804

-52,523

-52,084

-45,476

-42,487

-42,695

-41,914

-29,180

-24,430

-23,721

-27,460

-21,144

-17,806

-16,717

-15,598

-14,775

-8,600

-7,420

-5,200

-5,128

Other income (expense):
Interest income

2,856

-

-

-

3,831

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Interest expenses

2,314

-

-

-

181

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Interest income, net

-

-

4,226

3,546

-

2,850

2,480

2,115

1,173

698

727

689

441

252

159

131

117

13

11

6

3

0

0

Change in fair value of Series A redeemable convertible preferred stock liability

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-22

-37

Other expenses, net

116

36

31

63

50

-33

72

-4

34

36

104

142

52

-

-

-

-

-

-

-

-

-

-

Total other income, net

426

-

4,195

3,483

3,600

-

2,408

2,119

1,139

-

623

547

389

-

159

131

117

-

-

-

-

-

-

Net loss

-73,026

-95,975

-64,547

-57,321

-48,923

-49,201

-43,068

-40,368

-41,556

-41,252

-28,557

-23,883

-23,332

-27,208

-20,985

-17,675

-16,600

-15,585

-14,764

-8,594

-7,417

-5,222

-5,165

Other comprehensive income:
Net unrealized gain on marketable securities, net of tax

461

-224

-213

615

624

334

-139

82

11

-139

71

-89

-13

-

-

-

-

-

-

-

-

-

-

Comprehensive loss

-72,565

-96,199

-64,760

-56,706

-48,299

-48,867

-43,207

-40,286

-41,545

-41,391

-28,486

-23,972

-23,345

-27,374

-20,985

-17,675

-16,600

-15,585

-14,764

-8,594

-7,417

-5,222

-5,165

Net loss attributable to common stockholders

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-15,551

-10,747

-8,657

-5,987

-5,876

Basic and diluted net loss per common share

-1.20

-1.62

-1.07

-1.01

-0.87

-0.93

-0.83

-0.78

-0.87

-0.95

-0.66

-0.55

-0.60

-0.76

-0.58

-0.58

-0.56

6.01

-0.90

-4.84

-4.22

-3.53

-3.68

Weighted-average number of shares used in computing basic and diluted net loss per common share

60,787

60,417

60,098

56,539

56,231

53,039

52,050

51,742

47,770

-

43,259

43,063

39,125

36,652

36,353

30,381

29,441

29,666

17,288

2,218

2,052

1,698

1,594